Page 4 - Amarin News Today

Around the house: ABB poaches Holcim’s legal head as latest GC, US firetruck-maker REV Group ends GC hunt

Company maintains positive cash flow for fifth consecutive quarter

Amarin (NASDAQ:AMRN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation. Volatility and Risk Amarin has a beta of 1.87, indicating […]

Amarin (NASDAQ:AMRN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk. Valuation and Earnings This table compares Amarin and Roche’s top-line […]

StockNews.com assumed coverage on shares of Amarin (NASDAQ:AMRN – Free Report) in a report issued on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. AMRN has been the subject of a number of other research reports. Northland Securities reduced their price objective on Amarin from $2.00 to $1.25 in a report […]

Cross-platform frameworks have become a popular solution. They allow you to develop apps that run on different platforms while using the same code.

Icosapent Ethyl Capsule is a prescription medication used in conjunction with other medicines like statins to reduce the risk of heart attack, stroke and heart issues in those afflicted with...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

13D Management LLC lifted its position in Amarin Co. plc (NASDAQ:AMRN – Free Report) by 90.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,166,900 shares of the biopharmaceutical company’s stock after purchasing an additional 1,980,000 shares during the […]

Sanna Marin is forgoing politics to tackle new challenges at a London non-profit.